Previous study confirmed the significant efficacy and good safety of the combination of cipterbin and vinorelbine in the first-line treatment of HER2 positive advanced breast cancer patients who had not received anti-HER2-targeted therapy after previous taxus treatment (10). This evidence concerns the gene ERBB2 and breast cancer.